The global hair loss treatment market is estimated to be valued at US$ 3,592.3 million in 2020 and is expected to exhibit a CAGR of 6.2% during the forecast period (2020-2027).

Systemic androgen and genetic factors both contribute to hair loss. It can affect both men and women. The rising prevalence of alopecia, or hair loss, is likely to drive market expansion. According to the National Center for Biotechnology Information (NCBI), the global prevalence of severe androgenetic alopecia (AGA) was 15.33 percent in August 2015, with regional prevalence varying greatly. According to the same source, the risk of severe androgenetic alopecia (AGA) increases by 1.092 percent per year between the ages of 30 and 40.

The worldwide hair loss treatment market is predicted to rise due to product development and continuing clinical trials.

Over the forecast period, drug development for Hair Loss Treatment Market therapy is expected to support market growth. Cairo University, for example, has begun a clinical trial using topical Cetirizine for the treatment of androgenetic alopecia in women. The efficacy and tolerability of topical cetirizine in female patients with androgenetic alopecia are being evaluated in Phase II/III research (AGA). This interventional trial began in February 2020, with a completion date of December 2021.

In North America, research & development for the treatment of androgenetic alopecia is likely to drive market expansion.

Because of its research and development of medicines for androgenetic alopecia, North America is likely to dominate the worldwide hair loss treatment market. Follica, Inc., a biotechnology company developing a regenerative platform to treat androgenetic alopecia and other related disorders, for example, received encouraging feedback from the US Food and Drug Administration (FDA) for its FOL-004 Phase II trial, which was disclosed in December 2019. Following a successful safety and efficacy optimization trial for the treatment of hair loss in male androgenetic alopecia, the business progressed its primary program, FOL-004, into Phase III development in 2020.

Players to Watch

Viviscal, Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy's Laboratories Ltd, HCell Inc., Follica, Inc., Aurobindo Pharma, and Zydus Pharmaceutical